Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophagectomy | 7 | 2022 | 447 | 0.930 |
Why?
|
Lung Neoplasms | 21 | 2024 | 13102 | 0.790 |
Why?
|
Esophageal Neoplasms | 7 | 2022 | 1583 | 0.680 |
Why?
|
Pneumonectomy | 10 | 2024 | 1094 | 0.670 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2024 | 5221 | 0.610 |
Why?
|
Penetrance | 2 | 2014 | 381 | 0.490 |
Why?
|
Burnout, Professional | 1 | 2022 | 694 | 0.450 |
Why?
|
Genes, BRCA2 | 2 | 2014 | 618 | 0.440 |
Why?
|
Genes, BRCA1 | 2 | 2014 | 781 | 0.420 |
Why?
|
Pleural Neoplasms | 3 | 2022 | 607 | 0.420 |
Why?
|
Music Therapy | 2 | 2023 | 102 | 0.390 |
Why?
|
Mesothelioma | 3 | 2022 | 818 | 0.380 |
Why?
|
Breast | 2 | 2017 | 1969 | 0.380 |
Why?
|
Neoplasms, Second Primary | 2 | 2014 | 1061 | 0.350 |
Why?
|
Heterozygote | 2 | 2014 | 2804 | 0.350 |
Why?
|
Models, Genetic | 2 | 2014 | 3494 | 0.290 |
Why?
|
Breast Neoplasms | 6 | 2017 | 20822 | 0.280 |
Why?
|
Thoracic Surgery | 2 | 2023 | 719 | 0.270 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2021 | 685 | 0.270 |
Why?
|
Neoplasms | 7 | 2023 | 21683 | 0.260 |
Why?
|
Neoplasm Staging | 15 | 2024 | 11031 | 0.260 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 949 | 0.260 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 2728 | 0.250 |
Why?
|
Bronchial Fistula | 1 | 2023 | 85 | 0.220 |
Why?
|
Furans | 1 | 2024 | 194 | 0.220 |
Why?
|
Ketones | 1 | 2024 | 188 | 0.220 |
Why?
|
Vaginal Diseases | 1 | 2023 | 102 | 0.220 |
Why?
|
Pleural Diseases | 1 | 2023 | 139 | 0.210 |
Why?
|
Empyema | 1 | 2021 | 41 | 0.210 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 45 | 0.200 |
Why?
|
Hemangiosarcoma | 1 | 2024 | 239 | 0.200 |
Why?
|
Sarcoma | 2 | 2024 | 1897 | 0.200 |
Why?
|
Interneurons | 2 | 2016 | 577 | 0.190 |
Why?
|
Thymoma | 1 | 2022 | 186 | 0.190 |
Why?
|
Liposarcoma | 1 | 2024 | 333 | 0.190 |
Why?
|
Lymphatic Metastasis | 4 | 2021 | 2924 | 0.190 |
Why?
|
Carcinoma, Large Cell | 1 | 2021 | 113 | 0.190 |
Why?
|
Precancerous Conditions | 3 | 2017 | 975 | 0.190 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2023 | 360 | 0.180 |
Why?
|
Thymus Neoplasms | 1 | 2022 | 268 | 0.180 |
Why?
|
Thoracic Neoplasms | 1 | 2022 | 268 | 0.180 |
Why?
|
Keratins | 1 | 2021 | 515 | 0.180 |
Why?
|
Retrospective Studies | 26 | 2024 | 77449 | 0.180 |
Why?
|
Leiomyosarcoma | 1 | 2024 | 477 | 0.180 |
Why?
|
Palliative Care | 3 | 2023 | 3493 | 0.170 |
Why?
|
Gastrostomy | 1 | 2022 | 309 | 0.170 |
Why?
|
Thoracic Surgical Procedures | 1 | 2023 | 342 | 0.170 |
Why?
|
Morals | 1 | 2022 | 284 | 0.170 |
Why?
|
Pneumothorax | 1 | 2022 | 379 | 0.170 |
Why?
|
Bereavement | 1 | 2023 | 277 | 0.170 |
Why?
|
Hyperplasia | 3 | 2017 | 1185 | 0.160 |
Why?
|
Humans | 63 | 2024 | 744343 | 0.160 |
Why?
|
Chlamydia trachomatis | 1 | 2019 | 246 | 0.150 |
Why?
|
Ependymoma | 1 | 2020 | 334 | 0.150 |
Why?
|
raf Kinases | 1 | 2017 | 122 | 0.150 |
Why?
|
Learning Curve | 1 | 2018 | 208 | 0.150 |
Why?
|
Gastrectomy | 1 | 2021 | 663 | 0.150 |
Why?
|
Hospices | 1 | 2020 | 265 | 0.140 |
Why?
|
Contact Tracing | 1 | 2019 | 273 | 0.140 |
Why?
|
Organ Culture Techniques | 2 | 2015 | 813 | 0.140 |
Why?
|
Hydrocarbons | 1 | 2016 | 106 | 0.140 |
Why?
|
Preoptic Area | 1 | 2016 | 146 | 0.130 |
Why?
|
Aged | 23 | 2024 | 163280 | 0.130 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2017 | 215 | 0.130 |
Why?
|
Chlamydia Infections | 1 | 2019 | 365 | 0.130 |
Why?
|
Astrocytoma | 2 | 2017 | 790 | 0.130 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2020 | 721 | 0.130 |
Why?
|
Telencephalon | 1 | 2015 | 142 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1114 | 0.130 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2021 | 643 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9239 | 0.120 |
Why?
|
Drug Hypersensitivity | 1 | 2023 | 884 | 0.120 |
Why?
|
Carcinoma, Lobular | 2 | 2015 | 484 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6538 | 0.110 |
Why?
|
Adenocarcinoma | 2 | 2021 | 6364 | 0.110 |
Why?
|
Disease Transmission, Infectious | 1 | 2019 | 547 | 0.110 |
Why?
|
Hospice Care | 1 | 2020 | 672 | 0.110 |
Why?
|
Frail Elderly | 3 | 2023 | 693 | 0.110 |
Why?
|
Treatment Outcome | 14 | 2024 | 63114 | 0.110 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2021 | 990 | 0.110 |
Why?
|
Stress, Psychological | 3 | 2023 | 4245 | 0.110 |
Why?
|
Decision Support Systems, Clinical | 1 | 2021 | 1164 | 0.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11524 | 0.100 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2012 | 0.100 |
Why?
|
Protein Multimerization | 1 | 2017 | 970 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.100 |
Why?
|
Prognosis | 8 | 2021 | 29063 | 0.100 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 895 | 0.100 |
Why?
|
Coculture Techniques | 1 | 2015 | 1341 | 0.100 |
Why?
|
Calibration | 1 | 2014 | 816 | 0.100 |
Why?
|
Survival Rate | 6 | 2021 | 12788 | 0.100 |
Why?
|
Female | 26 | 2024 | 380194 | 0.100 |
Why?
|
Neural Inhibition | 1 | 2015 | 602 | 0.100 |
Why?
|
Homeodomain Proteins | 1 | 2021 | 2421 | 0.100 |
Why?
|
Mammary Glands, Human | 1 | 2012 | 199 | 0.100 |
Why?
|
Postoperative Complications | 6 | 2022 | 15295 | 0.100 |
Why?
|
Anticarcinogenic Agents | 1 | 2012 | 253 | 0.100 |
Why?
|
Decision Support Techniques | 1 | 2021 | 1956 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2022 | 2071 | 0.090 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2015 | 1101 | 0.090 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3586 | 0.090 |
Why?
|
Geriatric Assessment | 3 | 2023 | 1372 | 0.090 |
Why?
|
Chemoprevention | 1 | 2012 | 319 | 0.090 |
Why?
|
Heart Diseases | 1 | 2023 | 2788 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2183 | 0.090 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 522 | 0.090 |
Why?
|
Parents | 4 | 2023 | 3407 | 0.090 |
Why?
|
Carcinoma in Situ | 1 | 2015 | 806 | 0.090 |
Why?
|
Critical Illness | 1 | 2022 | 2670 | 0.090 |
Why?
|
Decision Making | 1 | 2023 | 3887 | 0.080 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2017 | 1581 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2015 | 3523 | 0.080 |
Why?
|
Lung | 3 | 2022 | 9856 | 0.080 |
Why?
|
HIV Antibodies | 1 | 2015 | 1322 | 0.080 |
Why?
|
Neural Stem Cells | 1 | 2015 | 851 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13695 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 1049 | 0.080 |
Why?
|
Middle Aged | 15 | 2022 | 213383 | 0.080 |
Why?
|
SEER Program | 1 | 2012 | 1508 | 0.080 |
Why?
|
Quality of Life | 3 | 2024 | 12804 | 0.080 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 25043 | 0.070 |
Why?
|
Forkhead Transcription Factors | 1 | 2014 | 1613 | 0.070 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2017 | 2043 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 4838 | 0.070 |
Why?
|
Adult | 14 | 2024 | 214055 | 0.070 |
Why?
|
Aged, 80 and over | 7 | 2022 | 57776 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3674 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4644 | 0.070 |
Why?
|
Mass Screening | 2 | 2019 | 5255 | 0.070 |
Why?
|
Fibroblasts | 1 | 2016 | 4161 | 0.070 |
Why?
|
Child | 9 | 2023 | 77709 | 0.070 |
Why?
|
Young Adult | 8 | 2023 | 56430 | 0.070 |
Why?
|
Antibodies, Neutralizing | 1 | 2015 | 1978 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 4034 | 0.060 |
Why?
|
Brain Neoplasms | 2 | 2017 | 8863 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1378 | 0.060 |
Why?
|
Paclitaxel | 2 | 2023 | 1708 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2012 | 2309 | 0.060 |
Why?
|
Male | 18 | 2023 | 350118 | 0.060 |
Why?
|
Age Factors | 2 | 2021 | 18370 | 0.060 |
Why?
|
Peptides | 1 | 2016 | 4409 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2017 | 17446 | 0.060 |
Why?
|
Nerve Net | 1 | 2015 | 2174 | 0.060 |
Why?
|
Cell Movement | 1 | 2015 | 5217 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2703 | 0.060 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3086 | 0.050 |
Why?
|
Clinical Competence | 1 | 2018 | 4687 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3479 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2015 | 2987 | 0.050 |
Why?
|
Risk Assessment | 3 | 2021 | 23338 | 0.050 |
Why?
|
Thymectomy | 1 | 2022 | 191 | 0.050 |
Why?
|
Hypesthesia | 1 | 2021 | 109 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2021 | 5078 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 6314 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6895 | 0.050 |
Why?
|
Transcription Factors | 1 | 2021 | 12208 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5535 | 0.050 |
Why?
|
Grief | 1 | 2023 | 247 | 0.050 |
Why?
|
Attitude to Death | 1 | 2023 | 382 | 0.050 |
Why?
|
Risk | 1 | 2012 | 9687 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39050 | 0.050 |
Why?
|
Risk Factors | 7 | 2022 | 72290 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 616 | 0.040 |
Why?
|
Taxoids | 1 | 2023 | 666 | 0.040 |
Why?
|
Epinephrine | 1 | 2023 | 792 | 0.040 |
Why?
|
Lymph Nodes | 2 | 2021 | 3474 | 0.040 |
Why?
|
Hospitalization | 1 | 2019 | 10262 | 0.040 |
Why?
|
HIV Infections | 2 | 2016 | 16718 | 0.040 |
Why?
|
Adolescent | 6 | 2024 | 85781 | 0.040 |
Why?
|
Remission Induction | 2 | 2015 | 2386 | 0.040 |
Why?
|
Mutation | 2 | 2014 | 29786 | 0.040 |
Why?
|
Indocyanine Green | 1 | 2020 | 239 | 0.040 |
Why?
|
Polypharmacy | 1 | 2021 | 294 | 0.040 |
Why?
|
Physician Assistants | 1 | 2021 | 193 | 0.040 |
Why?
|
Death | 1 | 2023 | 678 | 0.040 |
Why?
|
Tracheostomy | 1 | 2022 | 401 | 0.040 |
Why?
|
Length of Stay | 2 | 2022 | 6309 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 566 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 801 | 0.040 |
Why?
|
Anxiety | 2 | 2023 | 4297 | 0.040 |
Why?
|
Infant, Low Birth Weight | 1 | 2022 | 850 | 0.040 |
Why?
|
Nurse Practitioners | 1 | 2021 | 270 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9849 | 0.040 |
Why?
|
Time Factors | 4 | 2021 | 40075 | 0.040 |
Why?
|
HIV-1 | 1 | 2015 | 6939 | 0.040 |
Why?
|
Anastomotic Leak | 1 | 2018 | 162 | 0.040 |
Why?
|
Tumor Burden | 1 | 2023 | 1915 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 933 | 0.040 |
Why?
|
Lipopolysaccharides | 1 | 2024 | 2216 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12354 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 973 | 0.030 |
Why?
|
Caribbean Region | 1 | 2016 | 194 | 0.030 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2022 | 780 | 0.030 |
Why?
|
Naphthalimides | 1 | 2015 | 21 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 21 | 0.030 |
Why?
|
Daunorubicin | 1 | 2015 | 158 | 0.030 |
Why?
|
Surgical Flaps | 1 | 2023 | 1640 | 0.030 |
Why?
|
Survival Analysis | 2 | 2020 | 10252 | 0.030 |
Why?
|
United States | 5 | 2022 | 69872 | 0.030 |
Why?
|
Sexual Partners | 1 | 2019 | 730 | 0.030 |
Why?
|
Prosencephalon | 1 | 2016 | 303 | 0.030 |
Why?
|
Prospective Studies | 4 | 2023 | 53288 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2020 | 1261 | 0.030 |
Why?
|
Automation, Laboratory | 1 | 2014 | 101 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2879 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1531 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 192 | 0.030 |
Why?
|
Mexico | 1 | 2016 | 690 | 0.030 |
Why?
|
Dyspnea | 1 | 2021 | 1303 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2023 | 2057 | 0.030 |
Why?
|
Intention | 1 | 2016 | 341 | 0.030 |
Why?
|
Cytarabine | 1 | 2015 | 692 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 553 | 0.030 |
Why?
|
Microspheres | 1 | 2015 | 777 | 0.030 |
Why?
|
Mothers | 1 | 2023 | 2165 | 0.030 |
Why?
|
Vincristine | 1 | 2014 | 1039 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2015 | 913 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2019 | 1660 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 381 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 693 | 0.020 |
Why?
|
Emotions | 1 | 2023 | 2661 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 944 | 0.020 |
Why?
|
Androstadienes | 1 | 2012 | 346 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2017 | 1017 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3558 | 0.020 |
Why?
|
Patient Compliance | 1 | 2021 | 2684 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3528 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2266 | 0.020 |
Why?
|
Sexually Transmitted Diseases | 1 | 2016 | 624 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2274 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1574 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2015 | 2088 | 0.020 |
Why?
|
Communication | 1 | 2024 | 3749 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1375 | 0.020 |
Why?
|
Adenine | 1 | 2015 | 936 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3313 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2016 | 2715 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2015 | 1701 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3557 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1788 | 0.020 |
Why?
|
Mice | 4 | 2017 | 81183 | 0.020 |
Why?
|
Boston | 1 | 2022 | 9313 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3610 | 0.020 |
Why?
|
Reoperation | 1 | 2018 | 4201 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2242 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8324 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8642 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 2699 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2234 | 0.020 |
Why?
|
Tamoxifen | 1 | 2012 | 981 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2022 | 7785 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2015 | 1917 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 13881 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8663 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9146 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3616 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4933 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 7913 | 0.020 |
Why?
|
Pain | 1 | 2021 | 4986 | 0.020 |
Why?
|
Cell Lineage | 1 | 2015 | 2504 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4186 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 9959 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2014 | 2440 | 0.020 |
Why?
|
Smoking | 1 | 2022 | 8987 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2021 | 13989 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 8428 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2020 | 4371 | 0.020 |
Why?
|
Patient Readmission | 1 | 2018 | 3114 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10481 | 0.020 |
Why?
|
Genomics | 1 | 2020 | 5720 | 0.020 |
Why?
|
Mammography | 1 | 2015 | 2476 | 0.020 |
Why?
|
Animals | 4 | 2017 | 168757 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7279 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2014 | 3023 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2014 | 3462 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15540 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8388 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2020 | 11483 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4258 | 0.010 |
Why?
|
Physicians | 1 | 2021 | 4567 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2015 | 4462 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4554 | 0.010 |
Why?
|
Models, Statistical | 1 | 2017 | 5102 | 0.010 |
Why?
|
Medicare | 1 | 2020 | 6566 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25625 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15226 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7799 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11366 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12245 | 0.010 |
Why?
|
Neurons | 1 | 2020 | 9338 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 40561 | 0.010 |
Why?
|
Infant | 1 | 2022 | 35136 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5853 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 19229 | 0.010 |
Why?
|
Depression | 1 | 2019 | 7766 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20129 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6600 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2015 | 5708 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9438 | 0.010 |
Why?
|